Insight Molecular Diagnostics Inc.

OncoCyte Corp0KCC · BiotechUnited States

78% matchPublic

Insight Molecular Diagnostics Inc., which transitioned from its former name OncoCyte Corporation in June 2025, functions as a specialized diagnostics enterprise with operations extending across the United States and internationally. The company's core activities involve pioneering and marketing a diverse array of diagnostic solutions, including laboratory developed tests, kitted products intended solely for research, and comprehensive kitted clinical tests. Its developmental pipeline features advanced tools such as DetermaCNI, a blood-based monitoring system engineered to identify early cancer progression promptly after just one treatment cycle. Another significant offering, DetermaIO, is a gene expression assay designed to evaluate the tumor microenvironment, thereby helping to predict a patient's potential response to immunotherapies. In the critical field of organ transplantation, Insight Molecular Diagnostics provides several vital monitoring products. Both VitaGraft Kidney and VitaGraft Liver are blood-based tests that precisely measure the concentration of donor-derived cell-free DNA (dd-cfDNA) to assess the status of kidney and liver transplants, respectively. Additionally, GraftAssure represents a sophisticated dd-cfDNA test that leverages droplet digital PCR (ddPCR) technology to quantify dd-cfDNA levels by examining 48 predefined single nucleotide polymorphisms (SNPs). Beyond its product offerings, the company delivers various specialized services, including biomarker discovery, comprehensive assay design and development, support for clinical trials, and a range of general biomarker testing. Furthermore, Insight Molecular Diagnostics maintains a strategic partnership with Bio-Rad Laboratories, Inc. This collaboration focuses on the advancement and commercialization of kitted transplant products for both research use only and in vitro diagnostics applications, utilizing Bio-Rad's proprietary ddPCR instruments and reagents. Founded in 2009, the company's headquarters are situated in Nashville, Tennessee.

VeracyteVCYT · BiotechSouth San Francisco, United States

70% matchPublicAI 37/100 ▼Green 0/100 ▼

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.

Capio Biosciences, Inc.BiotechnologyUnited States

67% matchPrivate

Capio Biosciences is an oncology diagnostics company that develops advanced technologies for capturing and analyzing circulating tumor cells (CTCs) from whole blood. Its proprietary CapioCyte platform offers enhanced sensitivity compared to traditional methods, serving as a research tool designed to help oncologists make informed cancer treatment decisions.

As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.

INTEGRAGENALINT · BiotechFrance

66% matchPublic

IntegraGen develops genomic tests, molecular diagnostic products, and bioinformatics software for researchers, clinicians, and biopharma companies. The company specializes in oncology and genetic diseases, offering next-generation sequencing services, data analysis tools, and biomarker identification to support clinical research and diagnostics.